Loading...

APC/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APCCyanine7_CD8_Antibody_013019_updated.png
C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8 (clone 53-6.7) APC/Cyanine7 (left) or Rat IgG2a, κ APC/Cyanine7 isotype control (right).
  • 53-6dot7_APCCyanine7_CD8_Antibody_013019_updated.png
    C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8 (clone 53-6.7) APC/Cyanine7 (left) or Rat IgG2a, κ APC/Cyanine7 isotype control (right).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100713 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100714 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed
  2. Miragaia RJ, et al. 2019. Immunity. 50:493. PubMed
  3. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  4. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  5. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  6. Chan WY, et al. 2022. Infect Immun. 90:e0084618a. PubMed
  7. Cha JH, et al. 2022. J Biol Chem. 298:101817. PubMed
  8. Qu L, et al. 2022. Cell. 185:1728. PubMed
  9. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  10. Kiani Shabestari S, et al. 2022. Cell Rep. 39:110961. PubMed
  11. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  12. Yu Z, et al. 2022. Biomater Sci. 11:263. PubMed
  13. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  14. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  15. Azevedo PO, et al. 2023. NPJ Vaccines. 8:15. PubMed
  16. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  17. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  18. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  19. Elazar A, et al. 2022. Elife. 11:. PubMed
  20. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  21. Duhalde Vega M, et al. 2022. Sci Adv. 8:eabn6545. PubMed
  22. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  23. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  24. Zhu S, et al. 2023. Theranostics. 13:1042. PubMed
  25. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  26. Agrafiotis A, et al. 2023. iScience. 26:106055. PubMed
  27. Ke F, et al. 2023. Elife. 12:. PubMed
  28. Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed
  29. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed
  30. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  31. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  32. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  33. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  34. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  35. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  36. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  37. Berube A, et al. 2022. Viruses. 14:. PubMed
  38. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  39. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  40. Quinn K, et al. 2013. J Immunol. 191:5085. PubMed
  41. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  42. Cabrera-Mora M, et al. 2016. J Immunol. 197: 2748 - 2761. PubMed
  43. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  44. Vono M, et al. 2020. Cell Reports. 28(7):1773-1784.e5.. PubMed
  45. Kastenmüller K, et al. 2013. Infect Immun . 81:789. PubMed
  46. Fu Z, et al. 2019. Cell Rep. 28:159. PubMed
  47. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  48. Romain Bouziat et al. 2018. Cell host & microbe. 24(5):677-688 . PubMed
  49. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  50. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  51. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  52. Hirako I, et al. 2016. Nat Commun. 7:13277. PubMed
  53. Singhal A, et al. 2014. Sci Transl Med. 6:263. PubMed
  54. Chen J, et al. 2008. Blood. 111:5163. PubMed
  55. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  56. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  57. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  58. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  59. Park JH, et al. 2022. STAR Protoc. 3:101607. PubMed
  60. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  61. Wei H, et al. 2021. Malar J. 20:89. PubMed
  62. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  63. Spranger S, et al. 2013. Sci Transl Med. 26:200. PubMed
  64. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  65. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  66. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  67. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  68. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  69. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  70. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  71. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  72. Zhou Y, et al. 2016. Acta Pharmacol Sin. 10.1038/aps.2016.102. PubMed
  73. Lian G et al. 2018. eLife. 7 pii: e36158. PubMed
  74. Das S, et al. 2019. Oncogene. 383316. PubMed
  75. Wei SC, et al. 2019. Immunity. 50:1084. PubMed
  76. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  77. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  78. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  79. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  80. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  81. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  82. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  83. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  84. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  85. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
  86. Guo X, et al. 2020. Nat Commun. 11:2177. PubMed
  87. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  88. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  89. Zhang X, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:494. PubMed
  90. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  91. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  92. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  93. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  94. Marangoni F, et al. 2021. Cell. . PubMed
  95. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  96. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  97. Trotta E, et al. 2018. Nat Med. 24:1005. PubMed
  98. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  99. Hiltensperger M, et al. 2021. Nat Immunol. 22:880. PubMed
  100. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  101. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  102. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  103. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  104. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  105. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  106. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  107. Kang SJ, et al. 2022. Food Sci Anim Resour. 42:903. PubMed
  108. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  109. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  110. Soto-Díaz K, et al. 2021. Front Immunol. 12:734349. PubMed
  111. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  112. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  113. Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed
  114. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  115. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  116. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  117. Zheng J, et al. 2020. bioRxiv. . PubMed
  118. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
  119. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  120. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  121. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  122. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  123. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  124. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  125. França TT, et al. 2021. JCI Insight. 6:. PubMed
  126. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
  127. Flosbach M, et al. 2020. Cell Reports. 32(4):107957. PubMed
  128. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  129. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  130. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  131. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  132. Zheng J, et al. 2020. Nature. . PubMed
  133. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  134. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  135. Gough D, et al. 2014. Blood. 124:2252. PubMed
  136. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  137. Giampazolias E, et al. 2021. Cell. . PubMed
  138. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  139. Li J, et al. 2013. Arch Immunol Ther Exp (Warsz). 61:237. PubMed
  140. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  141. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  142. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  143. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  144. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  145. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  146. Hou Y, et al. 2021. Sci Transl Med. 13:. PubMed
  147. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  148. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  149. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  150. Wang Z, et al. 2021. Acta Pharm Sin B. 694:11. PubMed
  151. Martin MD, et al. 2020. Cell Rep. 31:107508. PubMed
  152. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
  153. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  154. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  155. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  156. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  157. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  158. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  159. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
  160. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  161. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  162. Koide S, et al. 2022. iScience. 25:103603. PubMed
  163. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
  164. Shoji M, et al. 2012. PLoS One. 7:e30302. PubMed
  165. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  166. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  167. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  168. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  169. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  170. Pradhan K, et al. 2021. J Immunol. 206:2980. PubMed
  171. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  172. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  173. Oh J, et al. 2021. Clin Cancer Res. 27:4781. PubMed
  174. Li H, et al. 2022. iScience. 25:104481. PubMed
  175. Chew HY, et al. 2020. Cell. 180(5):895-914. PubMed
  176. Lavoie S, et al. 2020. Gastroenterology. 158:1359. PubMed
  177. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  178. Zhang B, et al. 2021. Nature. 599:471. PubMed
  179. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  180. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  181. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  182. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  183. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  184. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  185. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  186. Yang H, et al. 2022. Viruses. 14:. PubMed
  187. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  188. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  189. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  190. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  191. Lynn GM, et al. 2020. Nat Biotechnol. 38:320. PubMed
  192. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  193. Lei F, et al. 2012. J Vis Exp. 63: 3986. PubMed
RRID
AB_312752 (BioLegend Cat. No. 100713)
AB_312753 (BioLegend Cat. No. 100714)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Spark YG™ 581 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark YG™ 593 anti-mouse CD8a (Flexi-Fluor™) Antibody 53-6.7 FC
Spark PLUS V475™ anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 795 anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 575 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 01/30/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account